A3AR agonists for the treatment of inflammatory arthritis

Details A3AR agonists for the treatment of inflammatory arthritis A3AR agonists for the treatment of inflammatory arthritis

2006-11-28

2006-11-28

Lewis, Patrick (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S045000, C536S027220, C536S027600, C536S027630

Reexamination Certificate

active

07141553

ABSTRACT:
The present invention concerns a method for the treatment of inflammatory arthritis, and in particular rheumatoid arthritis, by administering to the subject specific low dosages of N6-(3-iodobenzyl)-adenosine 5′-N-methyl-uronamide (IB-MECA) and 2-chloro-N6-(3-iodobenzyl)-adenosine-5′-N-methyl-uronamide (CL-IB-MECA).

REFERENCES:
patent: 5773423 (1998-06-01), Jacobson et al.
patent: 6323027 (2001-11-01), Burkly et al.
Baharav et al. International Journal of Molecular Medicine, (2002) vol. 10, No. Supplement 1, pp. S104, Meeting info: 7th World Congress on Advances in Oncology and the 5th International Symposium on Molecular Medicine, Hersonissos, Crete, Greece, Oct.
Bonvini et al, “Nuclear β-Catenin Displays GSK-3β- and APC-Independent Proteasome Sensitivity in Melanoma Cells”,Biochemica et Biophysica Acta1495:308-318 (2000).
Fang et al, “Phosphorylation and Inactivation of Glycogen Synthase Kinase 3 by Protein Kinase A”,Proc Nat'l Acad Sci97(22):11960-11965 (2000).
Ferkley et al, “GSK-3: New Thoughts on an Old Enzyme”,Developmental Biology225:471-479 (2000).
Fishman et al, “Evidence for Involvement of Wnt Signaling Pathway in IB-MECA Mediated Suppression of Melanoma Cells”,Oncogene21:4060-4064 (2002).
Olah et al, “The Role of Receptor Structure in Determining Adenosine Receptor Activity”,Pharmacology&Therapeutics85:55-75 (2000).
Poulsen et al, “Adenosine Receptors: New Opportunities for Future Drugs”,Bioorganic&Medicinal Chemistry6:619-641 (1998).
Szabó et al, “Suppression of Macrophage Inflammatory Protein (MIP)-1α Production and Collagen-Induced Arthritis by Adenosine Receptor Agonists”,British Journal of Pharmacology125:379-387 (1998).
Baharav, Ehud, et al, “The Anti-Inflammatory Effect of A3 Asenosine Receptor Agonists in Murine Autoimmune Arthritis Models”, International Journal of Molecular Medicine, v. 12, n. Supplement 1, pp. S42 (2003).
Baharav, Ehud, et al, “The Effect of Adenosine and the A3 Adenosine Receptor Agonist IB-MECA on Joint Inflammation and Autoimmune Diseases Models”, International Journal of Molecular Medicine, v. 10, n. Supplement 1, pp. S104 (2002).
Fang, G., et al, “Adenosine (ADO) Agonists Protect Mice from Death in a Model of Endotoxemia by Binding to A2Abut not A3ADO Receptors”, Abstracts of the Interscience Conference on AntiMicrobial Agents and Chemotherapy, v. 41, pp. 754, (2001).
Hasko, G., et al, “Stimulation of Adenosine 3 Receptors Exerts Anti-Inflammatory Effects in Acute and Chronic Models of Inflammation”, Drug Development Research, v. 43, n.1, pp. 39, (Jan. 1998).
Mabley, Jon, et al, “The A3 Adenosine Agonist, IB-MECA, Protects Against the Development of Arthritis and Reverses Established Arthritis”, FASEB Journal, vol. 16, n. 5, pp. A1044, (Mar. 22, 2002).
Szabo, Csaba, et al, “Suppression of Macrophage Inflammatory Protein (MIP)-1α Production and Collagen-Induced Arthritis by Adenosine Receptor Agonists”, British Journal of Pharmacology, v. 125, pp. 379-387, (1998).

Affiliated with

Also associated with

Rating

A3AR agonists for the treatment of inflammatory arthritis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with A3AR agonists for the treatment of inflammatory arthritis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and A3AR agonists for the treatment of inflammatory arthritis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3688868